Storia in 5 fonti

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to findings presented in ASCO Annual Meeting’s plenary session.Men who received apalutamide (Erleada, Johnson & Johnson) and ADT in the neoadjuvant and adjuvant settings survived longer without recurrence or

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo3 mesi fa

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

originale

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

Confronto fonti

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

Timeline cronologica

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of…

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery…

For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death